Results 21 to 30 of about 104,823 (289)

Comparison of Intravitreal Bevacizumab versus Triamcinolone for the Treatment of Diffuse Diabetic Macular Edema [PDF]

, 2010
Background: Our purpose was to compare the effect of triamcinolone and bevacizumab (Avastin) on the retinal thickness and functional outcome in patients with diabetic macular edema. Methods and Materials: A collective of 32 patients, who had been treated
Haritoglou, Christos, Ulbig, Michael W., Kook, Daniel, Wolf, Armin, Neubauer, Aljoscha Steffen, Kreutzer, Thomas C., Al Saeidi, Rashid   +6 more
core   +1 more source

Bevacizumab (Avastin) [PDF]

American Journal of Neuroradiology, 2009
Bevacizumab is a humanized monoclonal antibody that was the first FDA approved therapy designed to inhibit angiogenesis. This paper will review the mechanism of action and clinical role of this antiangiogenic agent.
openaire   +2 more sources

Effective second-line treatment with cetuximab and bevacizumab in a patient with hepatic metastases of colorectal cancer and hyperbilirubinemia [PDF]

, 2007
Background: Irinotecan-based second-line chemotherapy of metastatic colorectal cancer (CRC) is effective, it might, however, be contraindicated in cases of severe liver dysfunction due to advanced liver metastases.
Moosmann, Nicolas, Schulz, Christoph, Laessig, Dorit, Michaely, Henrik Jakob, Heinemann, Volker   +4 more
core   +1 more source

A randomised trial evaluating Bevacizumab as adjuvant therapy following resection of AJCC stage IIB, IIC and III cutaneous melanoma : an update [PDF]

, 2008
At present, there are no standard therapies for the adjuvant treatment of malignant melanoma. Patients with primary tumours with a high-Breslow thickness (stages IIB and IIC) or with resected loco-regional nodal disease (stage III) are at high risk of ...
Middleton, M. (Mark), Corrie, P, Middleton, M, Dunn, J., East, C, Lorigan, P; id_orcid, Hern, A., Biswas, S., Wrigley, J., Lorigan, P., Wrigley, J, Dunn, Janet A., Marshall, A. (Andrea), Corrie, P., East, C., Marshall, A.   +15 more
core   +1 more source

Physicochemical and Functional Similarity Assessment Between Proposed Bevacizumab Biosimilar BAT1706 and Reference Bevacizumab

Drugs in R&D, 2023
Background BAT1706 is a proposed biosimilar of bevacizumab, a vascular endothelial growth factor A (VEGF-A)-targeting biologic used to treat several different cancers, including metastatic colorectal cancer. A comprehensive physicochemical and functional
Di Cao, Chunping Deng, Guangying Wang, Xiong Mei, Jianhua Xie, Yuanmei Liu, Yujie Liu, Yili Yang, Shengfeng Li, Cuihua Liu   +9 more
doaj   +1 more source

Adjuvant bevacizumab in patients with melanoma at high risk of recurrence (AVAST-M) : preplanned interim results from a multicentre, open-label, randomised controlled phase 3 study [PDF]

, 2014
Background: Bevacizumab, a monoclonal antibody that targets VEGF, has shown restricted activity in patients with advanced melanoma. We aimed to assess the role of bevacizumab as adjuvant treatment for patients with resected melanoma at high risk of ...
N. Davidson (7671467), J. P. Nobes (7671491), P. Lorigan (7671500), Harries, M., C. G. Kelly (7671473), A. Marshall (7671452), M. R. Middleton (7671458), Dunn, Janet A, Houston, Stephen J, Board, Ruth E., Steve Nicholson (7671470), Lorigan, P., Waterston, A.M., Nobes, Jenny P., Gore, M.E., Kelly, Charles G, Danson, S., Nathan, Paul D, Nathan, Paul D., Kumar, S., Middleton, Mark R., Davidson, Neville, Marples, M., Nobes, Jenny P, Waterston, Ashita M, Young, G., Dunn, J., Nathan, P.D., Lorigan, Paul; id_orcid, Houston, S., Danson, Sarah J, M. Gore (7671464), Davidson, D., Board, R.E., M. Marples (7671476), Dunn, Janet A., Nobes, J.P., Marshall, E., Corrie, P., S. J. Danson (7671479), Marshall, A., Middleton, Mark R, Board, Ruth E, Middleton, M.R., Marshall, Ernest, Gore, Martin, Marples, Maria, Corrie, Pippa G, P. D. Nathan (7671461), G Young (7671497), E. Marshall (7241588), Houston, Stephen J., Young, Gemma, Nicholson, Steve, A. M. Waterston (7671488), Kelly, Charles G., P. G. Corrie (7671449), S. J. Houston (7671482), Kelly, C.G., Corrie, Pippa G., M. Harries (7671494), Marshall, Andrea, Kumar, Satish, S. Kumar (746162), Nicholson, S., Waterston, Ashita M., R. E. Board (7671485), Harries, Mark, Danson, Sarah J., Marshall, A. (Andrea)‏, Lorigan, Paul, J. A. Dunn (7671455)   +71 more
core   +1 more source

Treatment with Tumor-Treating Fields Therapy and Pulse Dose Bevacizumab in Patients with Bevacizumab-Refractory Recurrent Glioblastoma: A Case Series

Case Reports in Neurology, 2016
Patients with bevacizumab-refractory recurrent glioblastoma multiforme (GBM) have a poor prognosis. We propose that instead of continuing on bevacizumab, patients should switch to treatment with Optune™, a novel antimitotic Tumor-Treating Fields ...
George Ansstas, David D. Tran
doaj   +1 more source

A Comparative Parallel Study of Pharmacokinetics and Immunogenicity Following Single Intravenous Administration of Bevacizumab Biosimilar RPH-001 (Manufactured by R-Pharm Group, Russia) and Avastin® (Manufactured by F. Hoffmann-La Roche Ltd., Switzerland) in Healthy Male Volunteers

Разработка и регистрация лекарственных средств, 2019
Introduction. Bevacizumab is a monoclonal IgG1 antibody that binds to and inhibits the biologic activity of human vascular endothelial growth factor (VEGF). Bevacizumab is used as a targeted monoor combination therapy for different solid tumors.
M. A. Kolganova, N. S. Bagaeva, Yu. V. Medvedev, I. E. Shohin, A. V. Demchinskaya, T. N. Palkina, D. A. Salazanov, G. E. Konopleva, M. S. Sheremeteva, Sh. Z. Archuadze, Ya. V. Lavrovsky, A. Yu. Savchenko, M. Yu. Samsonov   +12 more
doaj   +1 more source

Bevacizumab in Ovarian Cancer

New England Journal of Medicine, 2012
N Engl J ...
Mehmet S, Copur, Angela M, Obermiller, Ryan, Ramaekers   +2 more
openaire   +5 more sources

Real-World Cost-Effectiveness of Bevacizumab With First-Line Combination Chemotherapy in Patients With Metastatic Colorectal Cancer: Population-Based Retrospective Cohort Studies in Three Canadian Provinces

MDM Policy & Practice, 2021
Background. Real-world evidence can be a valuable tool when clinical trial data are incomplete or uncertain. Bevacizumab was adopted as first-line therapy for metastatic colorectal cancer (mCRC) based on significant survival improvements in initial ...
Reka E. Pataky, Jaclyn Beca, David Tran, Wei Fang Dai, Erind Dvorani, Wanrudee Isaranuwatchai, Stuart Peacock, Riaz Alvi, Winson Y. Cheung, Craig C. Earle, Scott Gavura, Kelvin K. W. Chan   +11 more
doaj   +1 more source